NEWSLETTER. April

Transcription

1 NEWSLETTER April

2 Since the initial newsletter was posted in January, Nyrada has been busy transitioning into a fully functioning company with new staff joining and the development program ramping up. This newsletter will restate our overall corporate strategy, provide a brief update on activities planned and those currently underway, and introduce new members of the team, including the first appointments to the newly established Scientific Advisory Board. Overall strategy A new and dynamic biopharmaceutical company developing human therapies for neuroprotection and metabolic related disorders. Nyrada s strategy is to demonstrate the therapeutic utility of its patented drug candidates towards commercialization in global markets. Applications are selected based on sound scientific rationale, significant unmet clinical need, compelling market opportunity, and the potential for favorable regulatory treatment with a clear path to approval.

3 The 3 drug candidates that Nyrada has selected and is currently developing have broad applications across a range of target indications, all of considerable interest to large pharmaceutical companies. These target indications are not niche markets.. they are large markets of considerable unmet need involving rehabilitation of stroke victims, the treatment of peripheral nerve disease in diabetic patients, and the large proportion of the community with poorly controlled high blood cholesterol levels. Our aim with each drug is to take it through early-stage clinical trials to establish safety and evidence of proof-of-concept. That allows a value of the asset to be determined, with the asset then being passed onto a larger pharma company via a straight sale, licensing, or a partnering arrangement, for them to complete the final steps of the regulatory process and commercialization. Nyrada is a US-registered company, but in the near-term we will be conducting our business largely in Australia. We are sharing offices and human resources with Noxopharm, and that means that we can save money in our formative stages while having access to all the services (drug manufacture, chemistry, regulatory affairs) we need. Once we are in the clinic in 2019, we anticipate relocating to the US. This will enable access to the US capital markets where we expect to get greater attention and better value for the story. It is the home of wealthy foundations and significant government funding, with the Company s therapeutic targets the subject of substantial acquisition activity. Current activities In the short time since Nyrada was established, the focus has been on setting up the infrastructure required to move forward with the 3 drug programs. This involves careful planning in terms of identifying and laying out the tasks that need to be completed in the coming months, preparing detailed budgets, and searching out and appointing the core management and science team. Nyrada has a vision of being able to block the progressive nature of many common neurodegenerative diseases and disorders, rather than just their symptoms. That vision has its basis in two proprietary drugs that address two key underlying pathologies common to many diseases of the human nervous system - excitotoxicity and inflammation. NYX-104 is our lead drug in the field of excitotoxicity, and NYX-205 in the field of neuroinflammation. NYX-104 is being developed as a neuroprotectant, a drug designed to protect the brain from the problem of excitotoxicity that follows any damage to the brain and which considerably worsens the original brain damage. This drug has potential use across a broad range of brain injuries, but our initial focus is on stroke damage. We envisage this drug being used to reduce the severity of paralysis following stroke and to reduce rehabilitation times.

4 NYX-205 is being developed as an anti-inflammatory drug, with a particular emphasis on the treatment of inflammation of the nervous system, but potential use across a wide range of inflammatory conditions including ulcerative colitis, sclerosing cholangitis, non-alcoholic steatohepatitis and pulmonary fibrosis. Our initial focus is on using this drug to treat loss of nerve function (peripheral neuropathy) that occurs in 30-50% of diabetic patients. NYX-330 is under development as a treatment for hypercholesterolemia, or elevated blood levels of LDL (low density lipoprotein) cholesterol where it presents a risk factor for cardiovascular disease. The objective is to develop an oral drug that can be used in combination with the standard statin cholesterol-lowering drugs, or for use in individuals unable to use statins for safety reasons. More information about the drug candidates undergoing development can be found in the January Newsletter, or by clicking the relevant link of the on the Nyrada website homepage New team members Nyrada is pleased to announce that two new Neuroscience Researchers joined the team in March. The appointments of Dr. Alexandra Suchowerska and Jasneet Parmar enable the company to further the necessary research that underpins our applications and build on the scientific knowledge we have, to ensure the course we navigate through preclinical development is optimal. Dr. Alexandra Suchowerska will utilize her extensive research experience and work alongside Dr. Benny Evison on the NYX-104 and NYX-205 programs. Alexandra completed her B.Sc. in 2011 at the University of Sydney majoring in physiology and immunology. In 2012, she achieved First Class Honours in the lab of Prof. Lars Ittner where she gained extensive research experience with various mouse models of Alzheimer s disease. In 2013, Dr. Suchowerska moved to the University of New South Wales (UNSW) to commence a Research Assistant position in the lab of A/Prof Thomas Fath. During her PhD at UNSW ( ), Alexandra s research focused on the connection between nerve cells and how these connections break down early in Alzheimer s disease pathology. She continues publishing with collaborators working on various neurological disorders. In 2017, Alexandra was appointed as a Postdoctoral Research Fellow in the School of Medical Sciences at UNSW, mentoring PhD students in the novel techniques she developed and mastered during her PhD.

5 Jasneet Parmar completed her B Med Sci (Hons in Pharmacology) in 2013 at UNSW Sydney, Australia. During her Honours program she studied the influence of hypoxic preconditioning, a neuroprotective therapy, on inflammation, in a model of neonatal brain injury in the lab of Dr. Nicole Jones. She began her PhD in 2014 at the Translational Neuroscience Facility, Department of Physiology at UNSW Sydney, Australia under the mentorship of Prof Gary Housley. During her candidature she worked extensively on the development of a brain injury model. In parallel she also studied the putative contribution of a calcium permeable ion channel in brain injury as a potential neuroprotective target for cerebellar strokes. Jasneet joined Nyrada Inc. in 2018 as a Neuroscience Researcher and is working alongside Dr. Benny Evison and Dr. Alexandra Suchowerska on the NYX-104 and NYX-205. With her background in brain injury, she hopes to find new avenues for development of novel drug targets for mitigating brain injury and other neurological deficits Scientific Advisory Board In the last newsletter we announced that Prof. Gary Housley had been appointed as Chair of the Nyrada Scientific Advisory Board. The Scientific Advisory Board s function is to provide general guidance to the Board of Directors on scientific and commercial strategies, and to advise the executive and scientific teams on the conduct of the various R&D programs. Prof. Gary Housley holds the Chair in Physiology at the University of New South Wales, where he is the founding Director of the Translational Neuroscience Facility. He brings thirty years of leadership experience prosecuting research programs in the Brain Sciences, spanning from neuroscience discovery to clinical trials. He completed M.Sc. and Ph.D. studies at the University of Auckland (New Zealand), and post-doctoral research in the U.S.A. and U.K. in cellular and molecular neuroscience in sensori-motor circuits. In 2005 he was awarded the prestigious Royal Society of New Zealand James Cook Fellowship in Health Sciences to undertake international collaborative studies on the molecular physiology of auditory neuropathy. He was recruited to UNSW Sydney in 2006 to establish the translational neuroscience initiative in the School of Medical Sciences.

6 He has published over 160 primary publications in the areas of molecular and systems neuroscience, receiving broad scientific and lay commentary, and his success in research translation is reflected by 7 patent filings and a National Health and Research Council funded multi-centre clinical trial of DNA therapeutics for auditory nerve regeneration. The impact of his research has been recognised by medals from both the New Zealand and Australian Physiological Societies. He has served on executive bodies of those Societies, is a board member of a several prominent neuroscience journals and is member of the operations groups for the Australian National Imaging Facility and the Sydney Brain Bank. The innovative brain injury model his research team has developed, recently published in the journal Translational Stroke Research, has been central to the identification of Nyrada Inc. lead compounds. He is a co-inventor of the Nyrada Inc. neuroprotection technology. Nyrada is pleased to announce that Prof. Housley will be joined on the Scientific Advisory Board by Prof. Gilles Lambert, a leading researcher and thought leader in the field of blood lipid metabolism. Dr. Gilles Lambert was awarded a PhD in Pathophysiology from the University of Paris in Gilles further specialized in lipidology, first as a post-doctoral fellow at the Molecular Disease Branch of the National Institutes of Health (Bethesda MD, USA) and then as a senior research fellow at the Heart Research Institute (Sydney, NSW, Australia). Dr. Lambert is currently Associate Professor in Cell Biology at University of Nantes Medical School (France) and a group leader within the laboratory of Nutrition and Metabolism of the University Hospital of Nantes. Since 2004, Dr Lambert has conducted seminal research projects on PCSK9, a major inhibitor of the LDL receptor. He received several competitive research grants in Australia and in France to study the cardiovascular benefits and potential side effects of PCSK9 inhibition Nyrada,Inc 2018 Mid-Year Briefing Sydney, June at 3pm Sofitel Sydney Wentworth Hotel, Phillip Street, Sydney RSVP info@nyrada.com